Related Experiment Video
Updated: Jun 26, 2025
07:20
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
14.0K
Kinetically Inert Platinum (II) Complexes for Improving Anticancer Therapy: Recent Developments and Road Ahead.
Tushar Ranjan Panda1, Malay Patra1
1Laboratory of Medicinal Chemistry and Cell Biology, Department of Chemical Sciences, Tata Institute of Fundamental Research, Homi Bhabha Road, Navy Nagar, 400005, Mumbai, India.
Chemmedchem
|May 17, 2024
Summary
Kinetically inert platinum (Pt) complexes show promise as next-generation chemotherapy drugs. These novel Pt drugs aim to overcome limitations like resistance and side effects associated with current platinum-based therapies.
Area of Science:
- Medicinal Chemistry
- Oncology
- Pharmacology
Background:
- Current platinum (Pt) drugs face challenges including deactivation, resistance, and toxic side effects.
- Significant research efforts are directed towards designing improved and safer Pt-based chemotherapeutic agents.
- Understanding the role of kinetic lability is crucial for optimizing Pt drug efficacy and safety.
Purpose of the Study:
- To review the potential of kinetically inert platinum complexes as next-generation chemotherapy drugs.
- To discuss the impact of kinetic lability on the pharmacology of existing Pt drugs.
- To highlight the unique pharmacological features of various kinetically inert Pt(II) complexes.
Main Methods:
- Literature review of platinum-based chemotherapy.
- Analysis of kinetic lability's influence on drug deactivation, efficacy, toxicity, and resistance.
- Categorization and discussion of different classes of kinetically inert Pt(II) complexes.
Main Results:
- Kinetically inert Pt complexes offer potential advantages over traditional Pt drugs.
- Reduced deactivation, improved antitumor efficacy, lower toxicity, and overcoming resistance are key benefits.
- Structurally diverse kinetically inert Pt(II) complexes exhibit distinct pharmacological profiles.
Conclusions:
- Kinetically inert platinum complexes represent a promising avenue for next-generation cancer chemotherapy.
- These complexes offer a strategy to mitigate the deficiencies of current platinum drugs.
- Further exploration of inert Pt(II) complexes could lead to more effective and safer cancer treatments.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
13.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.1K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K